突发重磅利好,拿下国内唯一抑郁症创新药临床“通行证”!000513三季报深度解读

碧湾APP半导体...
Dec 22, 2025

12月21日,丽珠医药集团宣布,其子公司丽珠制药厂收到国家药品监督管理局的批准,同意其1类创新药NS-041片新增“治疗抑郁症”适应症开展临床试验。NS-041片是一款新型高选择性KCNQ2/3激动剂,其作用机制与现有主流抗抑郁药不同,它通过调节钾离子通道来影响神经元活动,从而改善抑郁症状。此次获批后,NS-041将成为国内唯一一个同时开展癫痫和抑郁症临床研究的KCNQ2/3靶向药物。抑郁症在中国...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10